COHERENT CORP. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that COHERENT CORP. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Jun 30, 2018 | $321.08M | Aug 28, 2018 |
| FY2018 | Mar 31, 2018 | $294.75M | Aug 28, 2018 |
| FY2018 | Dec 31, 2017 | $281.47M | Aug 28, 2018 |
| FY2018 | Sep 30, 2017 | $261.50M | Aug 28, 2018 |
| FY2018 | Jun 30, 2017 | $273.72M | Aug 28, 2018 |
| FY2018 | Mar 31, 2017 | $244.99M | Aug 28, 2018 |
| FY2018 | Dec 31, 2016 | $231.82M | Aug 28, 2018 |
| FY2018 | Sep 30, 2016 | $221.52M | Aug 28, 2018 |
| FY2017 | Jun 30, 2016 | $241.47M | Aug 21, 2017 |
| FY2017 | Mar 31, 2016 | $205.11M | Aug 21, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $5.81B | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $4.71B | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | $5.16B | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $3.32B | Aug 16, 2024 |
| FY2020 | Jun 30, 2021 | $808.01M | Aug 20, 2021 |
| FY2020 | Mar 31, 2021 | $783.23M | Aug 20, 2021 |
| FY2020 | Dec 31, 2020 | $786.57M | Aug 20, 2021 |
| FY2020 | Sep 30, 2020 | $728.08M | Aug 20, 2021 |
| FY2020 | Jun 30, 2020 | $746.29M | Aug 20, 2021 |
| FY2020 | Mar 31, 2020 | $627.04M | Aug 20, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $49.36M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | ($156.15M) | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | ($259.46M) | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $234.76M | Aug 16, 2024 |
| FY2023 | Jun 30, 2021 | $297.55M | Aug 18, 2023 |
| FY2022 | Jun 30, 2020 | ($67.03M) | Aug 29, 2022 |
| FY2020 | Jun 30, 2019 | $107.52M | Aug 20, 2021 |
| FY2020 | Jun 30, 2018 | $88.00M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $95.27M | Aug 16, 2019 |
| FY2018 | Jun 30, 2016 | $65.49M | Aug 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $96.12M | Aug 16, 2024 |
| FY2024 | Jun 30, 2023 | ($37.12M) | Aug 16, 2024 |
| FY2024 | Jun 30, 2022 | $414.29M | Aug 16, 2024 |
| FY2023 | Jun 30, 2021 | $402.12M | Aug 18, 2023 |
| FY2022 | Jun 30, 2020 | $39.48M | Aug 29, 2022 |
| FY2020 | Jun 30, 2019 | $148.67M | Aug 20, 2021 |
| FY2020 | Jun 30, 2018 | $136.76M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $115.56M | Aug 16, 2019 |
| FY2018 | Jun 30, 2016 | $91.81M | Aug 28, 2018 |
| FY2017 | Jun 30, 2015 | $76.80M | Aug 21, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $581.92M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $478.79M | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | $499.60M | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $377.11M | Aug 16, 2024 |
| FY2020 | Jun 30, 2021 | $83.77M | Aug 20, 2021 |
| FY2020 | Mar 31, 2021 | $83.23M | Aug 20, 2021 |
| FY2020 | Dec 31, 2020 | $84.86M | Aug 20, 2021 |
| FY2020 | Sep 30, 2020 | $78.25M | Aug 20, 2021 |
| FY2020 | Jun 30, 2020 | $100.49M | Aug 20, 2021 |
| FY2020 | Mar 31, 2020 | $94.76M | Aug 20, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $926.45M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $854.00M | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | $1.04B | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $474.10M | Aug 16, 2024 |
| FY2020 | Jun 30, 2021 | $126.67M | Aug 20, 2021 |
| FY2020 | Mar 31, 2021 | $131.24M | Aug 20, 2021 |
| FY2020 | Dec 31, 2020 | $118.89M | Aug 20, 2021 |
| FY2020 | Sep 30, 2020 | $107.19M | Aug 20, 2021 |
| FY2020 | Jun 30, 2020 | $134.15M | Aug 20, 2021 |
| FY2020 | Mar 31, 2020 | $82.13M | Aug 20, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $633.60M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $545.73M | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | $634.03M | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $413.33M | Aug 16, 2024 |
| FY2023 | Jun 30, 2021 | $574.35M | Aug 18, 2023 |
| FY2022 | Jun 30, 2020 | $297.29M | Aug 29, 2022 |
| FY2020 | Jun 30, 2019 | $178.48M | Aug 20, 2021 |
| FY2020 | Jun 30, 2018 | $161.01M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $118.62M | Aug 16, 2019 |
| FY2018 | Jun 30, 2016 | $122.97M | Aug 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $440.84M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $346.82M | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | $436.06M | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $314.33M | Aug 16, 2024 |
| FY2023 | Jun 30, 2021 | $146.34M | Aug 18, 2023 |
| FY2022 | Jun 30, 2020 | $136.88M | Aug 29, 2022 |
| FY2020 | Jun 30, 2019 | $137.12M | Aug 20, 2021 |
| FY2020 | Jun 30, 2018 | $153.44M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $138.52M | Aug 16, 2019 |
| FY2018 | Jun 30, 2016 | $58.17M | Aug 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $14.91B | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $14.49B | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | $13.71B | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $7.84B | Aug 16, 2024 |
| FY2023 | Jun 30, 2021 | $6.51B | Aug 18, 2023 |
| FY2022 | Jun 30, 2020 | $5.23B | Aug 29, 2022 |
| FY2020 | Jun 30, 2019 | $1.95B | Aug 20, 2021 |
| FY2019 | Jun 30, 2018 | $1.76B | Aug 16, 2019 |
| FY2018 | Jun 30, 2017 | $1.48B | Aug 28, 2018 |
| FY2017 | Jun 30, 2016 | $1.21B | Aug 21, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $6.43B | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $6.54B | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $6.48B | Aug 16, 2024 |
| FY2023 | Jun 30, 2022 | $3.46B | Aug 18, 2023 |
| FY2022 | Jun 30, 2021 | $2.38B | Aug 29, 2022 |
| FY2020 | Jun 30, 2020 | $3.16B | Aug 20, 2021 |
| FY2020 | Jun 30, 2019 | $820.56M | Aug 26, 2020 |
| FY2019 | Jun 30, 2018 | $737.35M | Aug 16, 2019 |
| FY2018 | Jun 30, 2017 | $576.73M | Aug 28, 2018 |
| FY2017 | Jun 30, 2016 | $429.64M | Aug 21, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $5.64B | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $5.21B | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $4.99B | Aug 16, 2024 |
| FY2023 | Jun 30, 2022 | $3.62B | Aug 18, 2023 |
| FY2023 | Jun 30, 2021 | $3.41B | Aug 18, 2023 |
| FY2023 | Jun 30, 2020 | $2.08B | Aug 18, 2023 |
| FY2022 | Jun 30, 2019 | $1.13B | Aug 29, 2022 |
| FY2020 | Jun 30, 2018 | $1.02B | Aug 20, 2021 |
| FY2020 | Jun 30, 2017 | $900.56M | Aug 26, 2020 |
| FY2019 | Jun 30, 2016 | $782.34M | Aug 16, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.47B | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $4.46B | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | $4.51B | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $1.29B | Aug 16, 2024 |
| FY2023 | Jun 30, 2021 | $1.30B | Aug 18, 2023 |
| FY2022 | Jun 30, 2020 | $1.24B | Aug 29, 2022 |
| FY2020 | Jun 30, 2019 | $319.78M | Aug 20, 2021 |
| FY2020 | Jun 30, 2018 | $270.68M | Aug 26, 2020 |
| FY2019 | Jun 30, 2017 | $250.34M | Aug 16, 2019 |
| FY2018 | Jun 30, 2016 | $233.76M | Aug 28, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $584.37M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $664.94M | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $944.42M | Aug 16, 2024 |
| FY2023 | Jun 30, 2022 | $1.35B | Aug 18, 2023 |
| FY2022 | Jun 30, 2021 | $1.14B | Aug 29, 2022 |
| FY2020 | Jun 30, 2020 | $876.55M | Aug 20, 2021 |
| FY2020 | Jun 30, 2019 | $943.58M | Aug 26, 2020 |
| FY2019 | Jun 30, 2018 | $836.06M | Aug 16, 2019 |
| FY2018 | Jun 30, 2017 | $748.06M | Aug 28, 2018 |
| FY2017 | Jun 30, 2016 | $652.79M | Aug 21, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $909.20M | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $926.03M | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | $821.31M | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | $2.58B | Aug 16, 2024 |
| FY2020 | Jun 30, 2021 | $1.59B | Aug 20, 2021 |
| FY2020 | Jun 30, 2020 | $493.05M | Aug 20, 2021 |
| FY2020 | Jun 30, 2019 | $204.87M | Aug 26, 2020 |
| FY2019 | Jun 30, 2018 | $247.04M | Aug 16, 2019 |
| FY2018 | Jun 30, 2017 | $271.89M | Aug 28, 2018 |
| FY2018 | Jun 30, 2016 | $218.45M | Aug 28, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $3.69B | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | $4.10B | Aug 15, 2025 |
| FY2024 | Jun 30, 2023 | $4.31B | Aug 16, 2024 |
| FY2023 | Jun 30, 2022 | $2.30B | Aug 18, 2023 |
| FY2022 | Jun 30, 2021 | $1.38B | Aug 29, 2022 |
| FY2020 | Jun 30, 2020 | $2.26B | Aug 20, 2021 |
| FY2020 | Jun 30, 2019 | $467.00M | Aug 26, 2020 |
| FY2019 | Jun 30, 2018 | $439.01M | Aug 16, 2019 |
| FY2018 | Jun 30, 2017 | $342.02M | Aug 28, 2018 |
| FY2017 | Jun 30, 2016 | $235.92M | Aug 21, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | (1) | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | (2) | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | 1 | Aug 16, 2024 |
| FY2020 | Jun 30, 2021 | 0 | Aug 20, 2021 |
| FY2020 | Mar 31, 2021 | 0 | Aug 20, 2021 |
| FY2020 | Dec 31, 2020 | 0 | Aug 20, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Aug 20, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Aug 20, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Aug 20, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 0 | Aug 15, 2025 |
| FY2025 | Jun 30, 2024 | (1) | Aug 15, 2025 |
| FY2025 | Jun 30, 2023 | (2) | Aug 15, 2025 |
| FY2024 | Jun 30, 2022 | 1 | Aug 16, 2024 |
| FY2020 | Jun 30, 2021 | 0 | Aug 20, 2021 |
| FY2020 | Mar 31, 2021 | 0 | Aug 20, 2021 |
| FY2020 | Dec 31, 2020 | 0 | Aug 20, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Aug 20, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Aug 20, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Aug 20, 2021 |